Roth Capital Predicts Beyond Air FY2029 Earnings

Beyond Air, Inc. (NASDAQ:XAIR) – Equities researchers at Roth Capital issued their FY2029 earnings per share (EPS) estimates for Beyond Air in a research note issued on Tuesday, February 11th. Roth Capital analyst J. Wittes anticipates that the company will post earnings of $0.06 per share for the year. The consensus estimate for Beyond Air’s current full-year earnings is ($0.87) per share.

Beyond Air Price Performance

XAIR opened at $0.37 on Thursday. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.76 and a quick ratio of 5.38. The stock has a market capitalization of $28.24 million, a P/E ratio of -0.26 and a beta of -0.15. The company’s 50 day simple moving average is $0.41 and its 200-day simple moving average is $0.43. Beyond Air has a one year low of $0.30 and a one year high of $2.12.

Beyond Air (NASDAQ:XAIR) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.09. Beyond Air had a negative return on equity of 227.29% and a negative net margin of 2,369.17%. During the same period in the previous year, the business earned ($0.50) earnings per share.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Baldwin Wealth Partners LLC MA raised its position in shares of Beyond Air by 721.3% during the fourth quarter. Baldwin Wealth Partners LLC MA now owns 308,000 shares of the company’s stock worth $110,000 after acquiring an additional 270,500 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Beyond Air by 81.0% in the fourth quarter. Geode Capital Management LLC now owns 562,713 shares of the company’s stock valued at $202,000 after acquiring an additional 251,823 shares during the last quarter. Finally, Soros Fund Management LLC acquired a new stake in Beyond Air in the third quarter worth about $573,000. Institutional investors and hedge funds own 31.50% of the company’s stock.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.